tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Teva price target raised to $28 from $25 at Goldman Sachs

Goldman Sachs analyst Matt Dellatorre raised the firm’s price target on Teva (TEVA) to $28 from $25 and keeps a Buy rating on the shares.

Meet Your ETF AI Analyst

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1